Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Delayed Nasdaq Other stock markets 11:18:25 2024-05-10 EDT			5-day change	1st Jan Change
0.777 ^USD	-2.26%		+0.09%	-84.16%

03-15	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT
03-14	Quoin Pharmaceuticals Seeks M&A Opportunities	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quoin Pharmaceuticals Seeks M&A Opportunities	03-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-13	CI
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	03-04	DJ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	03-04	CI
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	02-08	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	12-18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome	23-10-24	CI
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA	23-09-13	CI
Quoin Pharmaceuticals Limited Seeks M&A	23-08-03	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Quoin Pharmaceuticals, Ltd. Doses First Patient in Open Label Netherton Syndrome Clinical Trial	23-03-21	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	23-03-09	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09	CI
Quoin Pharmaceuticals, Ltd. Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome	22-12-13	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients	22-10-18	CI
Quoin Pharmaceuticals : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 27, 2022 - Form 6-K	22-09-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Highlights

Filters